What are the recommended management options and peri‑operative considerations for a redo aortic valve replacement in an adult patient with a failed prosthetic aortic valve?

Redo Aortic Valve Replacement: Management and Perioperative Considerations

For a failed prosthetic aortic valve requiring redo intervention, surgical aortic valve replacement (redo SAVR) should be the preferred approach in patients without prohibitive surgical risk, particularly those under 70 years of age, with excellent contemporary outcomes showing 2.5% operative mortality in non-endocarditis cases. 1

Risk Stratification and Patient Selection

Immediate Risk Assessment

• Operative mortality for redo SAVR is 2.5% in non-endocarditis cases and 4.6% overall 1
• Endocarditis increases operative mortality risk 4-fold (HR: 3.990) and represents the primary driver of elevated redo surgical risk 1
• Lower left ventricular ejection fraction (LVEF) independently predicts both operative mortality (HR: 0.956) and long-term survival 1
• Longer cardiopulmonary bypass time correlates with increased operative mortality (HR: 1.006) 1

Long-Term Survival Expectations

• For patients under 70 years: 92.9% at 1 year, 83.6% at 5 years, and 73.1% at 10 years 2
• Overall redo SAVR survival: 90.5% at 1 year, 77% at 5 years, and 57.2% at 10 years with median survival of 12.7 years 2
• Pre-existing chronic kidney disease strongly predicts worse long-term survival 2

Redo SAVR vs. Valve-in-Valve TAVR Decision Algorithm

Choose Redo SAVR When:

• Patient age <70 years with acceptable LVEF 1, 2
• Small prosthetic valve size (<21mm) where valve-in-valve would cause patient-prosthesis mismatch 3, 4
• History of prosthetic valve endocarditis (active or resolved) 3
• High risk of coronary obstruction based on CT assessment of coronary ostia height and sinus dimensions 3
• Need for concomitant cardiac surgery (coronary bypass, aortic root replacement, other valve surgery) 5, 3
• Non-fracturable prosthetic valve (certain mechanical or stented bioprosthetic designs) 4

Consider Valve-in-Valve TAVR When:

• Prohibitive surgical risk (STS-PROM >8% or predicted mortality >50%) 5, 3
• History of radiation heart disease with mediastinal fibrosis 3
• Multiple previous sternotomies (≥2 prior cardiac surgeries) 3
• Adequate prosthetic valve size (≥23mm) to avoid patient-prosthesis mismatch 6, 3
• Life expectancy >12 months despite high surgical risk 5

Comparative Outcomes Data

• 30-day mortality: redo SAVR 2.3-15.5% vs. valve-in-valve TAVR 0-17% (no significant difference in meta-analysis) 7, 6
• Permanent pacemaker requirement: 8.3% TAVR vs. 14.6% redo SAVR 6
• Severe patient-prosthesis mismatch: 3.3% redo SAVR vs. 13.5% valve-in-valve TAVR 6
• Moderate or greater paravalvular leak: 5.5% redo SAVR vs. 21.1% valve-in-valve TAVR 6

Preoperative Evaluation Requirements

Mandatory Imaging

• Transthoracic echocardiography to assess prosthetic valve dysfunction mechanism (stenosis vs. regurgitation), severity, ventricular function, pulmonary hypertension, and other valve disease 5
• Transesophageal echocardiography when prosthetic valve integrity is questioned or endocarditis suspected 5
• Cardiac catheterization with coronary angiography to evaluate for coronary artery disease requiring concomitant bypass 5
• CT angiography of chest/abdomen/pelvis if considering valve-in-valve TAVR to assess coronary obstruction risk, vascular access, and prosthetic valve dimensions 5

Critical Clinical Assessment

• Document presence/absence of prosthetic valve endocarditis through blood cultures, inflammatory markers (CRP, ESR), and serial echocardiography 5, 1
• Quantify LVEF precisely as values <50% significantly impact operative risk and long-term outcomes 1
• Assess renal function (eGFR, creatinine) as chronic kidney disease predicts worse survival 2
• Evaluate frailty status using validated tools (gait speed, grip strength, mini-nutritional assessment) 5
• Calculate STS-PROM score as baseline surgical risk estimate 5

Surgical Principles for Redo SAVR

In Non-Endocarditis Cases

• Standard redo sternotomy with cardiopulmonary bypass 5
• Explant failed prosthesis and debride annulus of calcification and pannus 5
• Implant appropriately sized prosthetic valve (mechanical or bioprosthetic based on age, anticoagulation tolerance, and patient preference) 5
• Operative mortality only slightly greater than primary AVR in stable patients without endocarditis 5

In Prosthetic Valve Endocarditis Cases

• Extensive debridement of infected tissue, abscesses, and non-viable annulus 5
• Send debrided tissue for culture and pathology especially if blood cultures negative 5
• Use autologous or heterologous pericardium for patch reconstruction rather than synthetic materials due to superior infection resistance 5
• Consider homograft root replacement for extensive aortic root destruction 5
• Continue IV antibiotics for 6 weeks postoperatively 5
• Timing is critical: progressive cardiac decompensation necessitates urgent surgery before infection control, particularly with staphylococcal infections 5

Postoperative Management

Anticoagulation Strategy

• Mechanical valve: warfarin with INR 2.0-3.0 indefinitely 8
• Bioprosthetic valve: warfarin with INR 2.0-3.0 for 3-6 months, then aspirin 75-100mg daily 8
• Concurrent atrial fibrillation: continue oral anticoagulation indefinitely regardless of valve type 8

Surveillance Protocol

• Baseline transthoracic echocardiography at 1-3 months post-surgery 8
• Repeat echocardiography at 5 years, 10 years, then annually for bioprosthetic valves 8
• Annual cardiology follow-up at Primary Valve Center mandatory 8
• More frequent imaging if risk factors for early degeneration (age <60 years, renal failure, diabetes) or new symptoms develop 8

Red Flag Symptoms Requiring Urgent Evaluation

• New or worsening dyspnea, syncope, or heart failure symptoms 8
• Fever (concern for prosthetic valve endocarditis) 8
• Significant bleeding on anticoagulation 8

Common Pitfalls to Avoid

• Do not assume valve-in-valve TAVR is automatically lower risk – patient-prosthesis mismatch and paravalvular leak rates are significantly higher than redo SAVR 6
• Do not delay surgery in endocarditis cases waiting for infection control – progressive cardiac decompensation mandates urgent intervention 5
• Do not overlook concomitant coronary disease – coronary angiography is essential as many patients require concurrent bypass 5
• Do not use redo SAVR operative mortality data that includes endocarditis cases when counseling non-endocarditis patients – the 2.5% mortality in non-endocarditis cases is dramatically better than the 4.6% overall figure 1